Sanofi has grown revenue 5.0% a year over three years and 3.9% a year over five, with earnings per share compounding at −1.5%. Revenue growth, 3-year annual rate: +5.0% (Drug Manufacturers - General median +6.3%). Revenue growth, 5-year rate: +3.9%, growth has picked up over the last three years. Earnings per share, 3-year rate: −1.5%, earnings lagged revenue: the growth is costing something. Years of annual history on file: 11, FY2015 to FY2025, as filed.

SNYSanofi

Healthcare

$40.07-11% 1Y

$40.07

$39.5252 weeks$49.59

Is it growing?

Mixed

Neither accelerating nor breaking down: earnings up +44% year on year, but operating margin narrowing (−7.0 points).

1 good, 1 to watch, 1 neutral

Revenue trend+6% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +4% a year.

Earnings trend+44% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing faster than revenue, so margins or the share count are helping.

Margin direction−7.0 points operating

Trailing-twelve-month operating margin, 14.5% now against 21.5% a year earlier.

All from SEC EDGAR, as of Dec 31, 2025.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is SNY growing?

Sanofi has grown revenue 5.0% a year over three years and 3.9% a year over five, with earnings per share compounding at −1.5%.

+5.0%

Revenue growth, 3-year annual rate · Drug Manufacturers - General median +6.3% · steady growth, ahead of inflation · compounded from fiscal years as filed

Revenue growth, 5-year rate: +3.9%
Revenue growth, 5-year rate · +5.0% over three · growth has picked up over the last three years
Earnings per share, 3-year rate: −1.5%
Earnings per share, 3-year rate · revenue +5.0% · earnings lagged revenue: the growth is costing something
Years of annual history on file: 11
Years of annual history on file · FY2015 to FY2025, as filed